SPOP and prostate carcinoma: Our findings obtained from novel SPOP‐mutated prostate cancer PDX and organoid models stress that prostate cancers, especially SPOP‐mutated subtype, can be effectively treated by the BET and CBP/p300 dual inhibitor.